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Abstract
The increasing diversity in both substrates and functions of matrix metalloproteinases (MMPs) makes these enzymes central regulators in the
complex tumor ecosystem composed of cancer cells and their microenvironment. In the majority of cancers, membrane-associated and extracellular
proteases are mainly produced by host cells including inflammatory cells, endothelial cells, pericytes and fibroblasts. Recent data based on in vitro
and in vivo studies have demonstrated the relevance of these enzymes in multiple processes controlling cancer growth, angiogenesis and metastatic
dissemination. This review will present the emerging MMP-related features of cancer cells and host cells.
© 2007 Elsevier Ltd. All rights reserved.
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1. The tumor ecosystem
Neoplastic cells have been the focus of interest in can-
cer research for many years. This approach has contributed
to deciphering the molecular determinants of carcinogenesis,
leading to the discovery that alterations in specific oncogenes
and tumor suppressor genes have causal roles in the initia-
∗ Corresponding author. Tel.: +32 4 366 25 69; fax: +32 4 366 29 36.
E-mail address: agnes.noel@ulg.ac.be (A. Noe¨l).
tion and progression of tumors. In this context, the traditionally
prevailing explanation of metastasis is that during cancer pro-
gression, tumor cells acquire, through the accumulation of
multiple genetic alterations, the ability to surmount a variety of
obstacles including shedding from the primary tumor, intrava-
sation into blood or lymphatic vessels, survival into circulation,
extravasation and growth at a secondary site [1]. However, this
tumor cell-centered view of cancer development has largely
ignored the contribution of the tumor microenvironment to the
malignant phenotype. Historically, the importance of tumor
1084-9521/$ – see front matter © 2007 Elsevier Ltd. All rights reserved.
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microenvironment during cancer progression has already been
recognized more than 100 years ago in the “seed and soil”
hypothesis proposed by Paget in 1889 [2]. As important as
tumor cells (“seeds”) are the diverse environments (“soils”) that
tumor cells encounter as they progress throughout the body.
A current definition of the “seed and soil” hypothesis is that
primary and secondary tumor nodules consist of a complex
ecosystem composed of cellular and non-cellular components.
The cellular compartment includes not only tumor cells them-
selves, but also blood or lymphatic endothelial cells, pericytes,
smooth muscle cells, (myo)fibroblasts, adipocytes, immune and
inflammatory cells [3]. The non-cellular compartment consists
of the various components of the extracellular matrix (ECM),
whose composition directly and indirectly influences the phe-
notype of the cellular compartment. The ECM is not simply
an extracellular scaffold; it also acts as a reservoir of biologi-
cally active molecules, such as growth factors and cytokines [4].
Some ECM components can express cryptic biological functions
upon proteolysis. Hence, the important ECM remodelling asso-
ciated to cancer progression influence cellular behaviour and
phenotype.
A tumor is now viewed as a complex evolving ecosystem.
One characteristic of all ecosystems is that minor alterations
in one of the partners may cause dramatic reorganisation of
the whole system. As a consequence, the tumoral stroma has
a strong influence on many steps of tumor development and
progression [5,6]. Morphological evidence of host participation
in invasion and metastasis are as follows: (1) desmoplasia con-
sisting of fibroblast-like cells and excessive deposit of ECM; (2)
inflammation and immune response represented by infiltration
of lymphocytes, macrophages, mast cells and dendritic cells; and
(3) angiogenesis evidenced by newly formed blood and lymph
vessels [7].
2. MMPs as key molecular determinants of Paget’s
“seed and soil” concept
Paget’s concept of tumor cells being seeds that need appro-
priate soils (organ environment) to grow and disseminate [2]
remains a valid concept that requires precise explorations at
the molecular level. The communication between the different
cellular (tumor islets and stroma) and non-cellular compart-
ments of the tumor microenvironment is by large mediated by
the so-called protease web [8]. In normal tissue homeostasis,
the interacting network of proteases and their natural inhibitors
maintain a proteolytic balance. During cancer progression, this
balance is disturbed by overexpression of proteases including
at least matrix metalloproteases (MMPs) and related families of
proteases, the ADAMs (a disintegrin and metalloproteases) and
ADAMTS (ADAM with thrombospondin repeats). This imbal-
ance alters the non-cellular compartment, which in turn activates
downstream molecular effectors leading to the establishment of
a milieu permissive for tumor progression, invasion and dissem-
ination.
The MMPs form a family of structurally and function-
ally related zinc endopeptidases which collectively are able of
degrading virtually all ECM components [9–11]. The produc-
tion and activities of MMPs are precisely regulated at the level
of transcription, activation of the precursor zymogens, interac-
tion with specific ECM components, inhibition by endogenous
inhibitors, and endocytosis [10,12]. Tissue inhibitors of metal-
loproteinases (TIMPs) control the local activities of MMPs in
tissues [13–15]. MMPs display a large set of ECM and non-ECM
substrates (Tables 1 and 2). They act as processing enzymes that
perform highly selective and limited cleavage of specific sub-
strates including growth factors and their receptors, cell adhesion
molecules, cytokines, chemokines, apoptotic ligands and angio-
genic factors [8,12].
Data supporting the role of proteases in cancer progression
derive from in vitro and in vivo experiments demonstrating: (1)
a correlation between protease expression and cell invasion and
metastasis; (2) a modulation of the invasive properties by cell
transfection with the cDNA of proteases and their inhibitors;
(3) a reduction of tumor growth and/or metastatic potential
by using natural or synthetic protease inhibitors, neutralizing
antibodies or antisense oligonucleotides; and (4) a modula-
tion of tumor growth and metastasis in MMP-deficient mice
[4,8,9,11,12,16–18]. However, MMP functions are much more
complex than initially anticipated; some MMPs playing a para-
doxical protective role in tumor progression [19,20], and others
displaying opposite functions depending upon the stage of can-
cer progression [8,11,21].
Recently, the emphasis has been to reveal the gene expres-
sion signatures of primary tumors, which have been associated
with their metastatic potential [22,23]. Interestingly, these anal-
yses have hinted at the importance of stroma-related genes and
some MMPs have been identified in specific gene expression
signature. MMP1 and MMP9 are among the 70 genes compos-
ing a gene signature able to predict distant metastasis in lymph
node negative breast cancer patients [23]. Moreover, MMP1 and
MMP2 have been described as genes that selectively mediate
lung metastasis in a mouse model of breast cancer [24] and as
members of a lung metastasis gene signature for human breast
cancers [25].
In addition, emerging evidence suggests that MMPs also con-
tribute to the elaboration of a so-called “pre-metastatic niche”.
According to this novel concept, certain primary tumor cells can
release soluble factors that induce a specific population of non-
malignant haematopoietic cells to mobilize and engraft distant
organ tissue, thereby establishing a “pre-metastatic niche” [26].
This process includes proteolytic matrix turnover and secre-
tion of soluble growth factors and chemokines that create a
permissive microenvironment for incoming circulating cancer
cells [27]. Primary tumor cells release VEGF-A, TGF and
TNF that in turn, induce the expression of chemoattractants
by lung endothelium and myeloid cells, facilitating thereby the
homing of tumor cells to the pre-metastatic niche within lung
parenchyma [28]. MMP9 expressed in lung macrophages and
endothelial cells promotes the invasion of lung tissues by tumor
cells [29] (Fig. 1).
Altogether these data identify MMPs as central regulators of
cancer progression. An important issue is actually to identify the
individual functions of MMPs and determine the cellular source
of each MMP at specific steps of cancer progression.
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Table 1
Selected extracellular matrix and cell surface-associated substrates of MMPs involved in cancer progression






ECM breakdown Cell migration MT1, MT2 and MT3-MMPs regulate
basement membrane transmigration
[42,16]
Liberation of cryptic domain Cell migration MT1-MMP generates a fragment of
laminin 5 promoting motility [111]
Increase growth factors
bioavailability
Angiogenesis (stimulation) MMP9 mobilizes VEGF sequestered
in ECM [81]
Release of anti-angiogenic fragments Angiogenesis (inhibition) MMP9 cleaves type IV collagen and
generates tumstatin [85]. MMP3,
MMP9, MM12, MMP13 and
MMP20 generate endostatin by
cleaving type XVIII collagen [86]
Cell surface molecules
E-cadherin Dissociation of epithelial cells Cell–cell adhesion MMP3 and MMP7 release
E-cadherin fragment [33]
Tissue-transglutaminase (tTG) Cell migration MT1-MMP degrades tTG and
promotes cell adhesion and
locomotion [113]
Fas-L Release of membrane-bound Fas
ligand (mFasL)
Cell apoptosis MMP7 cleaves Fas-L [34] MMP3
produced by stromal cells releases
mFas-L and has pro-apoptotic effect
on neighbouring epithelial cells [49]
Integrin Activation of v3 Angiogenesis MT1-MMP activates v3 [110]
CD44 Cell migration MT1-MMP cleaves cell
membrane-associated CD44 [112]
Table 2
Selected soluble substrats of MMPs involved in cancer progression
Substrates Impacts Biological processes
affected
Representative examples
Growth factors binding proteins
IGF-BP Increase IGF bioavailability Cell proliferation MMP3 degrades IGF-BP1 [101] - MMP7
generates bioactive IGF-II by degrading
IGF-II/IGFBP-2 complex [103]
TGF complex Release of TGF Cell proliferation,
angiogenesis
MMP2 and MMP9 release TGF from an
inactive complex consisting of TGF,
TGF latency-associated protein and
latent-binding protein [87]
Chemokines/cytokines




MMP8-deficiency in mice is associated
with sustained inflammation [20,83]
IL8 (CXCL8) interleukin-8 Activation of IL8 Chemoattraction
inflammation
MMP9 potentiates ten fold IL8 [88]
MCP-3 (monocyte chemo-attractant protein-3) Chemoattraction
inflammation
MMP2 cleaves (MCP-3), converting an
agonist to a potent receptor antagonist
[104]
SDF-1 (CXCL12) Inactivation of SDF-1 Chemoattraction MMP1, MMP2, MMP3, MMP13,
MT1-MMP inactivate SDF-1 [89]
IL2-receptor Cleavage of receptor Immune response MMP9 down-regulates T cell proliferation
by cleaving IL2-receptor [102]
Proteases
Pro-MMP Activation of MMP Proteolysis Cascade of pro-MMP activation [10]
Plasminogen Release of anti-angiogenic
molecule
Angiogenesis (inhibition) MMP12 generates angiostatin by
plasminogen cleavage [71]
Protease inhibitor
1 proteinase inhibitor Generation of bioactive
fragment
Sensitivity to natural killer
cells
MMP11 reduces the sensitivity of tumor
cells to natural killer cells [21]
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Fig. 1. MMP production in primary tumor and pre-metastatic niche. MMPs are produced by host cells and/or tumor cells. MMP9 is widely expressed in host and
tumor compartments at both primary and secondary sites. The MMP9 production is induced in pre-metastatic lung endothelial cells and macrophages by VEGF
secreted by primary tumors [21]. This MMP-9 induction precedes and promotes lung metastasis. EMT = Epithelial to Mesenchymal Transition.
3. MMPs and tumor cells
Only a few MMPs are exclusively expressed by tumor
cells themselves and most MMPs secreted by tumor cells are
also produced by host cells (Fig. 1). Two recently cloned
epithelial MMPs (MMP21 and MMP26) are also expressed by
macrophages and fibroblasts in vivo and in culture [30]. MMP7
(matrilysin) appears to be quite unique in its almost restricted
expression in tumor cells. MMP7 is expressed in benign and
malignant tumors that arise from the glandular epithelium and
its secretion is regulated in a polarized system [31]. It influ-
ences early stages of tumorigenesis through an action on ECM
and non-ECM substrates [18]. MMP7 regulates cell prolifer-
ation and apoptosis by cleaving the ectodomain of heparin
binding-epidermal growth factor (HB-EGF) precursor [32], and
affects cell–cell interaction and controls cell migration by releas-
ing soluble E-cadherin [33]. By shedding the ectodomain of
membrane-bound FasL (mFasL), MMP7 increases apoptosis in
normal surrounding cells, cancer cells being themselves refrac-
tory to proapoptotic signal [34].
Among MMPs, MMP19 displays unique structural features
and tissue distribution. MMP19 is expressed in normal human
epidermis and downregulated during malignant transformation
and dedifferentiation [35,36]. In a model of methylcholanthrene-
induced chemical carcinogenesis, MMP19−/− mice develop
less fibrosarcomas and with a longer latency period than wild-
type littermates [37]. In contrast, host MMP19-deficiency was
associated with an acceleration of the angiogenic response after
malignant keratinocyte transplantation [19]. These apparently
paradoxical results may reflect different roles of MMP19 at
different steps of cancer progression.
Overexpression of several MMPs (MMP2, MMP3, MMP9,
MMP13, MT1-MMP) have been associated to the epithelial to
mesenchymal transition (EMT), a fundamental biological pro-
cess where epithelial cells lose their polarity, cell–cell adhesion
and adopt a mesenchymal morphology appropriate for migra-
tion [38]. In addition, both MMP1 and MMP7 contribute to
EMT by degrading E-cadherin, a cell–cell adhesion molecule
[33]. Epilysin (MMP28), the newest member of the MMP fam-
ily is expressed in basal keratinocyte in the skin [39] and seems
to contribute in EMT [40].
It has long been assumed that carcinoma cells would pro-
duce by themselves proteolytic enzymes or recruit them from
host cells in an effort to degrade basement membrane for invad-
ing surrounding tissue. Surprisingly, tumor cells have been
reported to cross ECM barriers through non-proteolytic pro-
cess by exerting physical and mechanical forces that distort
matrix architecture [41]. Originally characterized as type IV
collagenases, MMP2 and MMP9 were viewed as essential pro-
teases for BM-invasive events. However, transfection of COS
cells with their cDNAs does not improve BM degradation
and invasion [42]. Instead, MMP2 produced by mesenchymal
cells and MMP9 secreted by inflammatory cells (macrophages
and neutrophils) are now viewed as key regulators of patho-
logical angiogenesis [43,44]. Among several MMPs tested,
only membrane-associated MMPs (MT1-MMP, MT2-MMP and
MT3-MMP) can serve as direct-acting proteases that are able of
dissolving BM during cell migration [42]. Interestingly, MT4-
MMP produced by breast carcinoma cells does not directly affect
in vitro cell invasion [42,45], but promotes in vivo the forma-
tion of metastasis through a control of vessel architecture [45].
These observations emphasize the multiple functions of MMPs
controlling various events related to cancer progression.
It is worth noting that the expression of the tumor cell-derived
proteases is frequently modulated by stromal microenvironment
and that important crosstalk are established between cancer cells
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and host cells leading to a regulation of protease expression in
both the tumor and host compartments [5].
4. MMPs and host cells
The tumor microenvironment contains several resident cell
types (fibroblasts and vascular cells) and migratory cells derived
from the bone marrow that play pivotal roles in the growth of
primary tumor and the formation of metastasis.
4.1. Fibroblasts
Cancer cells might stimulate fibroblasts to synthesize MMPs
in a paracrine manner through the secretion of interleukins, inter-
ferons, growth factors and EMMPRIN [4,10,46]. Fibroblasts
constitute therefore an important source of MMPs including
mainly MMP1 [47], MMP2 [48], MMP3 [49], MMP9, MMP11
[21,50], MMP13 [47] and MT1-MMP [17,51]. MMP2 produced
by fibroblasts can bind the surface of tumor cells through interac-
tion with for instance MT1-MMP and integrin v3 [48,52,53].
The expression of MMP13 has been co-localized with that of
MT1-MMP and MMP2 suggesting their contribution in a pro-
teolytic cascade [47,54].
MMP11 has been clearly established as a stromal factor
favouring the implantation of cancer cells in an aberrant envi-
ronment [21]. An increased number of apoptotic cancer cells
can be found in MMP11-deficient mice indicating that host
MMP11 protects tumor cells towards apoptosis [55]. Surpris-
ingly, MMP11 function differs throughout cancer history, it is
an enhancer for primary tumor development, but a repressor for
metastatic dissemination [21].
The role of fibroblasts-derived MMPs has been investigated
in xenograft models in which tumorigenic and not tumorigenic
cells are cotransplanted with fibroblasts [56], as well as in
the matrix-inserted surface transplantation model [5,44]. The
tumor promoting effect of fibroblasts in xenografts is reduced
when their ability to produce activated MMPs is inhibited by
TIMP2 or synthetic MMP inhibitor [57]. Interestingly, MMP11-
null fibroblasts [58] or MT1-MMP-null fibroblasts [59] do not
support in vivo growth of tumor cells whereas corresponding
wild-type fibroblasts promoted tumor development. It is worth
noting that upregulation of MMPs is one of the physiological
changes that occur when fibroblasts undergo senescence, which
may be an important component of the generation of a pro-
oncogenic tissue environment that contributes to the increased
incidence of cancers that occur with age [60,61]. Accordingly,
fibroblasts that have been forced into senescence by DNA dam-
age increased the growth of cancer cells in a MMP-dependent
manner [61]. The tumor microenvironment can be a potent car-
cinogen, not only by facilitating cancer progression, but also by
stimulating tumor formation. A stromal enzyme such as MMP3
can cause sustained EMT and malignant transformation in cul-
tured cells and genomically unstable mammary carcinomas in
transgenic mice [49]. In this context, MMP3 has been reported
to induce the expression of an alternative spliced form of Rac1
which causes an increase in cellular reactive oxygen species
[62].
4.2. Macrophages
Tumor-associated macrophages (TAM) represent a major
component of the lymphoreticular infiltrates of tumors [63,64].
High numbers of TAM have been observed in many tumors. The
extent of the macrophage infiltrate correlates positively with
angiogenesis and negatively with prognosis in some cancers
[65,66]. In macrophage-deficient mice crossed with polyoma
middle-T oncoprotein (PyMT mice), the incidence and initial
rate of primary mammary tumors are not distinguishable to those
of wild type mice, but the rate of tumor progression was slowed
and their metastatic ability was almost completely abrogated
[67]. Macrophages may have both pro- and anti-tumor activities.
TAMs are educated by the tumor microenvironment, so that they
adopt a trophic role that facilitates angiogenesis, matrix break-
down and tumor cell motility. They are able to produce a variety
of MMPs including MMP1, 2, 7, 9 and 12 [68]. TAM-derived
MMP9 appears to play a critical role in angiogenesis and pro-
gressive growth of human ovarian tumors in mice [69]. However,
the production of the inhibitor of angiogenesis, angiostatin, has
been correlated with TAM production of elastolytic metallopro-
teinases in a murine model of Lewis lung cell carcinoma [70].
Macrophage MMP12 is required for the generation of angio-
statin [71]. MMP12-deficient mice develop more gross Lewis
lung carcinoma pulmonary metastases than wild type counter-
parts, thus providing a role for MMP12 in suppressing the growth
of lung metastases [72]. Although little is know about in vivo
functions of MMP12, it is a candidate anti-target, but further
experiment are required in MMP12-deficient mice to validate
this concept [8].
4.3. Mast cells
Mast cells have been shown to accumulate within and around
the tumors of different origins [73,74]. In experimental models,
the injection of mast cell suspensions into rats leads to the accel-
eration of tumor growth [75]. In the same way, using a transgenic
mouse model that expresses human papilloma virus (HPV)-16
genes in basal keratinocytes, Coussens et al. showed that car-
cinogenesis was accompanied by the infiltration of mast cells
[76,77]. On the contrary, decreasing the number of mast cells
leads to suppression of tumor growth [78] and pre-malignant
angiogenesis was ablated in mast cell deficient HPV-16 trans-
genic mice [76]. The inhibition of degranulation suppresses
tumor growth [75], suggesting that the tumor-promoting activ-
ity of mast cells is related with granule-associated mediators.
Degranulating mast cells release different proteases includ-
ing MMP2 and MMP9 [79], as well as serine proteases, such
as tryptase and chymase which can activate latent MMP3
and MMP9 [79,80]. Interestingly, the release of MMP9 by
inflammatory cells infiltrating normal pancreatic islets mobilizes
sequestered vascular endothelial growth factor (VEGF) which
triggers an angiogenic switch and promotes tumor growth [81].
4.4. Neutrophils
Polymorphonuclear neutrophils (PMN) are crucial inflamma-
tory leukocytes in host protection from infection. Accumulating
Author's personal copy
A. Noe¨l et al. / Seminars in Cell & Developmental Biology 19 (2008) 52–60 57
evidence also indicates their important role during cancer pro-
gression. They represent an important source of MMP8 also
called the neutrophil collagenase [82] and MMP9 [44]. MMP8
is produced primarily by PMNs and is released from the specific
granules at sites of inflammation [82]. In contrast to other MMP-
deficient mice, MMP8 null mice challenged with carcinogens
showed a markedly increased susceptibility to tumorigenesis
[20], but this only occurred in male mice. This was the first
report of a MMP having a protective role in tumorigenesis,
so validating MMP8 as an anti-target in cancer therapy [8].
In skin tumors chemically induced in MMP8-null mice, a pro-
longed chronic accumulation of PMN that did not dissipate was
observed and associated to the reduction of bioactive molecule
processing such as LIX, a neutrophil chemoattractant [20]. LIX
bioactivity is increased in mouse upon N-terminal cleavage by
MMP8 and comparable results were obtained with the human
orthologues CXCL8/IL8 and CXCL5/ENA-78 [83]. Therefore,
although MMP8 was long thought functionally restricted to
ECM breakdown through collagenolysis, it is now viewed as
a key regulator of chemokine activities.
4.5. Vascular and perivascular cells
It is widely recognized that tumors required angiogenesis
to grow beyond a certain size. In addition to the sprouting
of neighbouring pre-existing vessels, tumoral angiogenesis is
supported by the mobilization of different cell types includ-
ing haematopoietic cells, endothelial progenitor cells derived
from the bone marrow leading to vasculogenesis, and mural
cells (pericytes, smooth muscle cells) promoting vessel stabiliza-
tion [84]. These processes involve a wide range of cell surface
molecules (integrins, selectins, cell adhesion molecules, growth
factor receptors) as well as soluble mediators including fibrob-
last growth factor (FGF), VEGF, angiopoietins, interleukins
(IL1, IL8), tumor necrosis factor- (TNF), TGF-. . . MMPs
are perfectly designed to regulate their activation/inactivation,
to control their biodisponibility by releasing them from ECM
and to generate inhibitors of angiogenesis through the cleavage
of molecules which do not display any angiogenic activity under
native conformation (Tables 1 and 2) [85–89].
Therefore, the roles of MMPs in angiogenesis are dual and
complex. Positive regulators of angiogenesis include at least
MMP1, MMP2, MMP9, MMP10 and MT-MMPs. MMP2 and
MMP9 have been shown to be critical for the “angiogenic
switch” when tumors become vascularized [90]. The impor-
tance of MMP2 and MT1-MMP in vessel formation is reflected
by embryonic lethality of double KO mice [91] and post-natal
lethality in MT1-MMP-deficient mice [92,93]. MT1-MMP con-
trol tumoral angiogenesis through diverse mechanisms reported
in previous reviews [17,51,94]. Whereas considerable data sug-
gest that MT-MMPs control endothelial cell tube morphogenesis
in 3D ECM [95–97], MMP1 and MMP10 (stromelysin-2) appear
to control the process of regression rather than morphogene-
sis [98]. MT1-MMP deficiency [95], but not that of MMP2
and/or MMP9 deficiency [44] directly affected the migration and
sprouting of endothelial cells from aortic rings. However, double
mutant MMP2−/−; MMP9−/− mice showed reduced angio-
genesis after transplantation of malignant keratinocytes [44].
This demonstrates the implication of different host cells dur-
ing angiogenesis, MMP2 being produced by mesenchymal cells
and MMP9 by neutrophils in this experimental model [44]. Inter-
estingly, MMP9 plays a key role in vasculogenesis through the
release of soluble ckit ligand allowing the transfer of hematopoi-
etic and endothelial stem cells from a quiescent to a proliferative
compartment in the bone marrow [99]. Furthermore, MMP9 reg-
ulates vessel stabilization by controlling pericyte recruitment
[100].
By their capacity to generate angiogenic inhibitors through
the cleavage of plasminogen, type IV or type XVIII colla-
gens, MMP3, MMP7, MMP9, MMP12, MMP13 and MMP20
are expected to be negative regulators of tumor angiogenesis
[85,86]. Similarly, MMP19 could be considered as an anti-
tumor target since its deficiency in mice has been associated
to accelerated angiogenesis [19].
4.6. Adipocytes
The adipocytes represent one of the most abundant cell
type surrounding breast cancer cells and may prove to be a
key player in the stromal-ductal epithelial cell–cell interactions
within the mammary microenvironment. Indeed, many tumors
break through the basement membrane and infiltrate fibrous tis-
sue barriers, resulting in immediate proximity to adipocytes.
Preadipocytes and adipocytes emerge as cells with the poten-
tial to affect growth and development of malignant breast cells
[105,106]. Adipocytes are highly active endocrine cells that
secrete numerous factors including growth factors, cytokines,
ECM proteins and MMPs [107,108]. Interestingly, adipocytes
appear to be involved in initial cancer cell survival in connec-
tive tissue and this effect is mediated, at least partly by MMP11
[109].
5. Conclusions
MMPs regulate a multitude of cell functions and are key reg-
ulators in a complex molecular network controlling both tumor
cell and host cell features. MMPs are implicated in virtually
all aspects of cancer progression and dissemination. Despite
structure and sequence homologies and substrates overlapping
between MMPs, different cell types express various MMPs at
specific steps of cancer progression. MMPs display diverse and
some time opposite effects depending upon the cellular source,
tissue location and step of cancer evolution considered. The
failure of clinical trials employing synthetic MMP inhibitors
in cancer chemotherapy has led to disappointing results [10],
but in the meantime led to the interesting concept that some
MMPs may actually serve the host in its defence against tumor
growth and evolution. This concept has been and is currently
being validated in human cancers and in different in vivo murine
models thanks to the recent generation of MMP-deficient mice.
Future efforts to identify which, where and when MMPs are
friends or foes will be essential to identify the specific targets
and anti-targets among the MMP family. Elucidation of their
in vivo substrates is also mandatory to determine their mecha-
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nisms of action and pave the way for appropriate drug design
for anti-cancer therapies [110–113].
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